This question tests monitoring requirements when switching between ACE inhibitors. The key patient-specific factor is that both medications are ACE inhibitors with similar effects on potassium and renal function, though the patient is switching to a different agent. Option A is correct because ACE inhibitors can cause hyperkalemia and affect renal function, and these parameters should be rechecked 1-2 weeks after any ACE inhibitor initiation or change, even when switching within the class. Option B (TSH) is unrelated to ACE inhibitor therapy. Option C (neutrophil count) is not routinely monitored for ACE inhibitors. Option D (magnesium) is not specifically affected by ACE inhibitors. The clinical pearl is that even when switching between agents in the same class, key safety parameters (potassium and renal function for ACE inhibitors) should be monitored to ensure the new agent is tolerated similarly to the previous one.

This question tests the pharmacist's response to a drug recall involving a high-risk medication with potential superpotency. The key patient-specific factor is that the patient has already taken today's dose from the recalled lot and warfarin has a narrow therapeutic index where superpotency could cause dangerous bleeding. Option B is correct because it addresses immediate patient safety by stopping the recalled product, ensures continuity of anticoagulation therapy with an unaffected lot at the same dose, and includes critical monitoring with an expedited INR check and prescriber notification. Option A is incorrect and dangerous because continuing a potentially superpotent warfarin could lead to supratherapeutic INR and bleeding. Option C is inappropriate because switching anticoagulants requires prescriber involvement and careful transition planning. Option D is incorrect because arbitrarily reducing the dose without knowing the actual potency could lead to subtherapeutic anticoagulation. The clinical pearl is that drug recalls involving narrow therapeutic index medications require immediate action, continued therapy with safe product, enhanced monitoring, and prescriber communication.

This question tests appropriate antibiotic substitution during a drug recall for pyelonephritis treatment. The key patient-specific factor is uncomplicated pyelonephritis requiring effective oral therapy, with the prescribed fluoroquinolone unavailable due to contamination risk. Option B is correct because trimethoprim-sulfamethoxazole is an appropriate alternative for pyelonephritis when local susceptibility supports its use, the duration (14 days) is appropriate for this indication, and it involves prescriber communication for the therapeutic change. Option A is dangerous because dispensing contaminated medication violates patient safety. Option C is incorrect because azithromycin is not recommended for pyelonephritis and the duration is too short. Option D is inappropriate because nitrofurantoin doesn't achieve adequate tissue levels for pyelonephritis treatment despite being effective for cystitis. The clinical pearl is that pyelonephritis requires antibiotics with good tissue penetration and appropriate duration; during shortages, alternatives must be selected based on local resistance patterns with prescriber involvement.

This question tests therapeutic interchange during a drug shortage for an ACE inhibitor in a patient with diabetes. The key patient-specific factor is that the patient has diabetes, making ACE inhibitors or ARBs preferred for renal protection, and she is currently well-controlled on combination therapy. Option A is correct because enalapril 10 mg twice daily provides an equivalent ACE inhibitor dose to lisinopril 20 mg daily, maintaining the same drug class benefits including renal protection in diabetes. Option B (losartan 25 mg) is suboptimal because it's a low starting dose of an ARB that may not maintain blood pressure control. Option C (captopril 12.5 mg once daily) is incorrect due to inadequate dosing - captopril requires multiple daily doses and this is below the typical starting dose. Option D is inappropriate because discontinuing antihypertensive therapy for 6 weeks could lead to uncontrolled hypertension and loss of renal protection. The clinical pearl is that during ACE inhibitor shortages, switching to another ACE inhibitor at equivalent doses maintains therapeutic benefits, while ARBs are reasonable alternatives if ACE inhibitors are unavailable.

This question tests dosage form conversion calculations during a drug shortage. The patient needs amoxicillin 880 mg (11 mL × 80 mg/mL) twice daily, requiring conversion to chewable tablets. To achieve 880 mg per dose using 250 mg tablets: 880 mg ÷ 250 mg/tablet = 3.52 tablets, which rounds to 3.5 tablets. Option B is correct with 3.5 tablets of the 250 mg strength twice daily providing the closest dose to the prescribed 880 mg. Option A (875 mg tablets) would provide a similar total dose but doesn't match the calculation. Option C (1.75 tablets of 500 mg) would give 875 mg, which is acceptable but the question asks for 250 mg tablet conversion. Option D (4 tablets of 250 mg) would provide 1000 mg, representing a significant overdose. The clinical pearl is that when converting between dosage forms during shortages, maintain the prescribed dose as closely as possible using available strengths, and consider the practicality of tablet splitting for pediatric patients.

This question tests monitoring requirements when switching between insulin products due to a recall. The key patient-specific factor is that the patient uses basal-bolus insulin therapy and is switching from a recalled insulin glargine with potential underdosing to a biosimilar product. Option A is correct because blood glucose monitoring is essential when switching insulin products, especially when the recalled product may have been underdosing (leading to potential hyperglycemia) and the new product may provide full dosing (risk of hypoglycemia if the patient adapted to underdosing). Option B (INR) is irrelevant as the patient is not on anticoagulation. Option C (digoxin level) is inappropriate as the patient is not taking digoxin. Option D (peak flow) is unnecessary as this change doesn't affect respiratory function. The clinical pearl is that insulin product switches, particularly involving recalls for dosing issues, require intensive glucose monitoring to detect and prevent hypoglycemia or hyperglycemia during the transition period.

This question tests proper documentation requirements for drug shortage interventions. The key factor is ensuring complete documentation for continuity of care, liability protection, and quality assurance. Option A is correct because comprehensive documentation should include the shortage details, communication with prescriber, specific therapy changes, patient counseling provided, and monitoring plans - all essential for patient safety and professional practice standards. Option B is inadequate because it only documents patient satisfaction without clinical details. Option C is insufficient and potentially dangerous because omitting shortage information could lead to confusion about therapy changes. Option D is inappropriate and unsafe because it documents advice to use expired medications. The clinical pearl is that drug shortage interventions require the same thorough documentation as any clinical intervention, including the reason for change, prescriber collaboration, patient education, and follow-up plans to ensure safe transitions in therapy.

This question tests therapeutic alternatives for metformin during a shortage, focusing on formulation switches and dose equivalence in type 2 diabetes management. The key patient-specific factors are the patient's current 1000 mg twice daily immediate-release dose, hemoglobin A1c of 7.4%, and normal renal function. Switching to metformin extended-release 2000 mg once daily with the evening meal is the best choice as it maintains total daily dose and glycemic control with a convenient once-daily regimen. Twice-daily extended-release lacks the evening dosing benefit for tolerability, increasing empagliflozin without prescriber input is inappropriate, and 500 mg once daily is subtherapeutic. A transferable clinical pearl is that metformin IR to ER conversions typically match total daily dose, with ER taken with meals to minimize GI effects. Pharmacists should apply a framework evaluating renal function, A1c control, and patient adherence when selecting alternatives.

This question tests therapeutic alternatives for lisinopril during shortage, focusing on equipotent ACE inhibitor conversion. The key patient-specific factor is the stable 20 mg lisinopril dose for hypertension. Enalapril 20 mg once daily is the best choice as it provides direct dose equivalence. 10 mg or 2.5 mg are subtherapeutic, 40 mg exceeds equivalence risking hypotension. A transferable clinical pearl is that lisinopril and enalapril share 1:1 dose conversion for most patients. Pharmacists should employ a framework using conversion charts and monitoring blood pressure post-switch.

This question tests therapeutic alternatives for metformin extended-release during shortage, emphasizing formulation switches and dose equivalence. The key patient-specific factors are the 2000 mg once-daily extended-release dose and availability of immediate-release 1000 mg tablets. Metformin immediate-release 1000 mg twice daily with meals is the best choice as it maintains total daily dose and minimizes GI upset. Once-daily 2000 mg immediate-release risks tolerability issues, 500 mg is subtherapeutic, stopping metformin disrupts control. A transferable clinical pearl is that ER to IR switches often divide doses with meals for better absorption and tolerance. Pharmacists should use a framework calculating total dose and assessing patient factors like meals.